Publications by authors named "Delphine Anger"
An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany.
Expert Rev Pharmacoecon Outcomes Res
February 2017
Introduction: Since 2007, the German Standing Vaccination Committee recommends HPV vaccination for girls aged 12-17 with a 2- (Cervarix®) or 4-valent (Gardasil®) vaccine. A 9-valent vaccine (Gardasil 9®) recently received a European market authorization in 2015.
Methods: A dynamic transmission model was calibrated to the German setting and used to estimate costs and QALYs associated with vaccination strategies.
Article Synopsis
- The ARAMIS model was used to analyze the cost-effectiveness of dolutegravir (DTG) in Canadian HIV patients, comparing it with several other treatments for both treatment-naive (TN) and treatment-experienced (TE) cases.
- Results showed that DTG was consistently more effective in increasing quality-adjusted life-years and was associated with significant cost savings compared to other treatments.
- The study concluded that DTG is a superior option for managing HIV due to its high efficacy and resistance barrier, making it the preferred choice in both TN and TE patient populations.
Herpes zoster (HZ; shingles) is a common viral disease that affects the nerves and surrounding skin causing a painful dermatomal rash and leading to debilitating complications such as, mainly, post-herpetic neuralgia (PHN). Currently, there is no effective treatment for HZ and PHN. The objective of this study was to assess the cost-effectiveness of a HZ vaccination program in Germany.
View Article and Find Full Text PDF